drugset / Trial / NCT00224016

Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition

NCT00224016

Phase 4 Completed 57 enrolled Watson Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate the safety and effectiveness of an anticholinergic drug treatment administered by transdermal patch to treat overactive bladder in children who have a neurological condition (e.g. spina bifida) that contributes to their overactive bladder.

Timeline

Start
2004-12
Primary completion
2007-04
Completion
2008-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Oxybutynin Small molecule 1.3 mg Other
Comparator Oxybutynin Small molecule 2.6 mg Other
Comparator Oxybutynin Small molecule 3.9 mg Other
Comparator Oxybutynin Small molecule 5 mg Other
Comparator Oxybutynin Small molecule 10 mg Other
Comparator Oxybutynin Small molecule 15 mg Other